- Home
- EVM vs INZY Comparison
EVM vs INZY Comparison
Compare EVM & INZY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVM
- INZY
- Stock Information
- Founded
- EVM 2002
- INZY 2015
- Country
- EVM United States
- INZY United States
- Employees
- EVM N/A
- INZY N/A
- Industry
- EVM Finance/Investors Services
- INZY Biotechnology: Pharmaceutical Preparations
- Sector
- EVM Finance
- INZY Health Care
- Exchange
- EVM Nasdaq
- INZY Nasdaq
- Market Cap
- EVM 228.0M
- INZY 188.2M
- IPO Year
- EVM N/A
- INZY 2020
- Fundamental
- Price
- EVM $9.36
- INZY $1.25
- Analyst Decision
- EVM
- INZY Strong Buy
- Analyst Count
- EVM 0
- INZY 8
- Target Price
- EVM N/A
- INZY $17.75
- AVG Volume (30 Days)
- EVM 55.8K
- INZY 677.6K
- Earning Date
- EVM 01-01-0001
- INZY 03-11-2025
- Dividend Yield
- EVM 4.01%
- INZY N/A
- EPS Growth
- EVM N/A
- INZY N/A
- EPS
- EVM 0.20
- INZY N/A
- Revenue
- EVM N/A
- INZY N/A
- Revenue This Year
- EVM N/A
- INZY N/A
- Revenue Next Year
- EVM N/A
- INZY N/A
- P/E Ratio
- EVM $47.61
- INZY N/A
- Revenue Growth
- EVM N/A
- INZY N/A
- 52 Week Low
- EVM $7.67
- INZY $1.24
- 52 Week High
- EVM $9.59
- INZY $7.80
- Technical
- Relative Strength Index (RSI)
- EVM 48.24
- INZY 31.42
- Support Level
- EVM $9.28
- INZY $1.24
- Resistance Level
- EVM $9.39
- INZY $1.43
- Average True Range (ATR)
- EVM 0.06
- INZY 0.10
- MACD
- EVM -0.01
- INZY 0.04
- Stochastic Oscillator
- EVM 33.33
- INZY 3.12
About EVM Eaton Vance California Municipal Bond Fund of Beneficial Interest $.01 par value
Eaton Vance California Municipal Bond Fund is an investment company with an objective to provide current income exempt from regular federal income tax, including alternative minimum tax, and, in state specific funds, taxes in its specified state. The company provides its solutions to individual investors, institutional investors, high net worth individuals, family office investors, and financial professionals. It offers a range of equity, income, and alternative strategies to institutional investors, both in the United States and internationally.
About INZY Inozyme Pharma Inc.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.